Haemonetics Announces Executive Leadership Updates

Core Insights - Haemonetics Corporation has announced changes to its Executive Leadership team, appointing Frank Chan as Executive Vice President and Chief Operating Officer, effective April 7, 2025, and Roy Galvin as Executive Vice President and Chief Commercial Officer, effective immediately [1][4] Group 1: Leadership Changes - Frank Chan will oversee research and development, regulatory affairs, global manufacturing, and supply chain operations, reporting to the President and CEO Chris Simon [2] - Roy Galvin, previously President of Global Plasma and Blood Center, will now manage the Global Hospital business and direct commercialization initiatives for the entire product portfolio [4] Group 2: Leadership Experience - Frank Chan brings over 25 years of experience in medical device and healthcare technology, having previously served as President of Acute Care & Monitoring at Medtronic, and held roles at Covidien and DePuy Orthopaedics [3] - Roy Galvin has over 25 years of experience in the global healthcare technology field, particularly in the Neuroscience and Orthopedic markets at Medtronic [4] Group 3: Company Strategy - Chris Simon emphasized that the addition of Chan and the expanded role for Galvin aligns with the company's long-range plan for growth and success [5]